On March 4th 2019, at the CROI conference in Seattle, USA, Chief Investigator Professor Saye Khoo presented the primary outcome analysis of the DolPHIN-2 study on behalf of the study team.
The study reveals that dolutegravir suppresses viral load faster than efavirenz in late pregnancy.
74 percent of women who received dolutegravir in their third trimester of pregnancy had undetectable viral load at the time of delivery, compared with only 43 percent of the women who were randomised to receive standard of care, efavirenz-based regimens.
Mothers and infants in DolPHIN-2 will be followed to 72 weeks after delivery.
The results of the trial have been covered and disseminated by numerous HIV organisations and highlighted in CROI conference reports including: